SH PHARMA (02607) fell more than 5%, dropping 5.11% to HK$11.71 by the time of writing, with a trading volume of HK$109 million. The decline follows the company's release of its Q3 2025 financial report.

For the first nine months of 2025, the company reported revenue of RMB 215.07 billion, up 2.60% year-on-year, while net profit attributable to shareholders rose 26.96% to RMB 5.147 billion. However, in Q3 alone, revenue increased 4.65% to RMB 73.479 billion, but net profit attributable to shareholders declined 38.13% to RMB 688 million, primarily due to higher asset impairment provisions during the quarter.